Business UpdateOct 19, 2026, 08:11 AM
ArriVent BioPharma: Firmonertinib Shows Strong Results in EGFR PACC-Mutant NSCLC
AI Summary
ArriVent BioPharma announced the publication of FURTHER Phase 1b results for firmonertinib in Cancer Cell. The results highlight firmonertinib's potential as a targeted therapy for treatment-naïve patients with advanced EGFR PACC-mutant non-small cell lung cancer (NSCLC). The publication details robust clinical activity, including high overall response rates and significant progression-free survival, as well as meaningful intracranial activity. These findings support ArriVent's ongoing global Phase 3 ALPACCA trial.
Key Highlights
- Firmonertinib showed 43% (160 mg) and 68% (240 mg) confirmed overall response rate (ORR) in front-line EGFR PACC-mutant NSCLC.
- Median progression-free survival (PFS) was 11.1 months (160 mg) and 16.0 months (240 mg) by blinded independent central review (BICR).
- Intracranial ORR was 47% (8/17) among patients with baseline brain metastases.
- 80% of evaluable patients achieved complete molecular response by cycle 3, correlating with better outcomes.
- Firmonertinib demonstrated enhanced in vitro potency against PACC-mutated EGFR compared to osimertinib.
- ArriVent is evaluating firmonertinib versus investigator's choice of osimertinib or afatinib in a Phase 3 trial (FURMO-006).
Price Impact
More from AVBP